EyebioKorea, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.eyebiokorea.com
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Phase 2
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- EyebioKorea, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06487039
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Busan Paik Hospital, Inje University, Busan, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- EyebioKorea, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05538949
- Locations
- 🇰🇷
Busan Paik Hospital, Inje University, Busan, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath